Journal Watch


karenskjeiKaren L. Skjei, M.D. was inspired to pursue a career in medicine after witnessing the impact of a lack of access to medical care during her 2 years in the U.S. Peace Corps in the Dominican Republic. She attended medical school at the University of California, San Francisco (UCSF), followed by a pediatric neurology residency at the Mayo Clinic in Minnesota. She then did a 2- year fellowship in Clinical Neurophysiology/Epilepsy at the Children's Hospital of Philadelphia. She is active in health disparities research and founded and leads the Health Equity Committee through the Pediatric Epilepsy Research Consortium.

After serving in academic leadership positions in epilepsy for 10 years, she chose to combat health disparities directly by setting up the first pediatric epilepsy practice in El Paso, Texas, a city of 850,000 with only a single pediatric neurologist.

Internationally she has given invited lectures in English and Spanish on a variety of pediatric epilepsy topics at regional education conferences organized by the American Epilepsy Society (AES), American Academy of Neurology and the International Child Neurology Society in locations as diverse as Ecuador, Paraguay, India and the Sudan. She has been editor of the ICNA Journal Watch since its inception in 2019.

She is a fellow of the AES and has published more than 13 peer-reviewed articles and two book chapters. She has won several major awards throughout her career including the Chancellor’s Award for Public Service at UCSF, the Mayo Brother’s Distinguished Fellows award at the Mayo Clinic and the Tower Award for Outstanding Faculty at the University of Texas at Austin. She founded the Pediatric Epilepsy Fellowship at the University of Texas at Austin and has garnered several teaching awards throughout her career. Perhaps most importantly, she has inspired many trainees to enter the fields of pediatric neurology and pediatric epilepsy and continues to mentor trainee from the undergraduate level through fellowship.

92 results - showing 61 - 70
1 2 3 4 5 6 7 8 9 10
Ordering
Details
Ratings
Dev Med Child Neuro
Dev Med Child Neuro
Updated August 26, 2014 11314 0
Dev Med Child Neurol
Aim The aim of this study was to examine whether vigabatrin treatment had caused visual field defects (VFDs) in children of school age who had received the drug in infancy. Method In total, 35 children (14 males, 21 females; median age 11y, SD 3.4y, range 8–23y) were examined by static Humphrey perimetry, Goldmann kinetic perimetry, or Octopus perimetry. The aetiologies of infantile spasms identified were tuberous sclerosis (n=10), other symptomatic causes (n=3), or cryptogenic (n=22). Results Typical vigabatrin-attributed VFDs were found in 11 out of 32 (34%) children: in one out of 11 children...
Read more Write review
 
0.0
 
0.0 (0)
Journal Of Paediatrics And Child Health
Journal Of Paediatrics And Child Health
Updated August 26, 2014 10835 0
J Paediatr Child Health. 2014 Jun 22
Encephalitis is a complex neurological syndrome caused by inflammation of the brain that occurs with highest incidence in children. It is challenging to diagnose and manage due to the variety of aetiologies and non-specific clinical presentations. We discuss the recent progress in clinical case definitions; review recent, large, prospective epidemiological studies; and describe aetiologies. We emphasise infectious causes relevant to children in Australasia but also consider emerging immune-mediated syndromes responsive to immune therapies. We identify priorities for future research in children, given the potential for climate change and international travel to influence the emergence of infectious agents in our...
Read more Write review
 
0.0
 
0.0 (0)
Pediatric Neurology
Pediatric Neurology
Updated August 26, 2014 15311 1
Pediatr Neurol. 2014 Jun 6
BACKGROUND: In spite of high occurrence of migraine headaches in school-age children, there are currently no approved and widely accepted pharmacologic agents for migraine prophylaxis in children. Our previous open-label study in children revealed the efficacy of cinnarizine, a calcium channel blocker, in migraine prophylaxis. A placebo-controlled trial was conducted to demonstrate the efficacy and safety of cinnarizine in the prophylaxis of migraine in children.
Read more Write review
 
0.0
 
0.0 (0)
Journal Of Nuclear Medicine
Journal Of Nuclear Medicine
Updated August 26, 2014 14402 0
J Nucl Med. 2014 May 5;55(7):1099-110
AIMS: A precise assessment of the drug-resistant epileptic pediatric population for surgical candidacy is often challenging, and to date there are no evidence-based guidelines for presurgical identification of the epileptogenic zone. To evaluate the usefulness of radionuclide imaging techniques for presurgical evaluation of epileptic pediatric patients, we compared the results of video-electroencephalography (EEG), brain MR imaging, interictal SPECT, ictal SPECT, subtraction ictal SPECT coregistered to MR imaging (SISCOM), and interictal PET with 18F-FDG.
Read more Write review
 
0.0
 
0.0 (0)
ICNA
ICNA
July 28, 2014 9174 1
Acta Paediatr. 2014 Jul 21
AIMS: There is a need for an objective assessment scoring system to evaluate the effectiveness of prophylactic drugs in paediatric migraine and the aim of this study was to evaluate the Paediatric Migraine Disability Assessment score (PedMIDAS).  
Read more Write review
 
0.0
 
0.0 (0)
Dr Paolo Curatolo
Dr Paolo Curatolo
Updated November 21, 2017 11387 0
Tuberous sclerosis complex (TSC) is a genetic multisystem disorder characterized by the development of hamartomas in several organs. Mutations in the TSC1 and TSC2 tumor suppressor genes determin overactivation of the mammalian target of rapamycin (mTOR) signaling pathway and subsequent abnormalities in numerous cell processes. As a result, mTOR inhibitors such as sirolimus and everolimus have the potential to provide targeted therapy for TSC patients. Everolimus has been recently approved as a pharmacotherapy option for TSC patients with subependymal giant-cell astrocytomas (SEGAs) or renal angiomyolipomas (AMLs). However, clinical evidence suggests that this treatment can benefit other TSC-associated disease...
Read more Write review
 
0.0
 
0.0 (0)
 
0.0
 
0.0 (0)
92 results - showing 61 - 70
1 2 3 4 5 6 7 8 9 10